CryoLife makes Medtronic executive Mackin CEO
This article was originally published in Clinica
CryoLife, which specializes in providing preserved human cardiac and vascular tissues for surgery, has appointed James Patrick (Pat) Mackin president and CEO. He joins from medtech giant Medtronic, where he worked since 2002, most recently as president of cardiac rhythm disease management, the firm’s largest operating division. Mr Mackin will join CryoLife on 2 September, replacing outgoing chief Steven Anderson, who will remain at the company as chair. Before joining Medtronic, Mr Mackin was at Genzyme for six years, and he also served in the US Army.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.